Comparing pharmaceutical pricing and reimbursement policies in Croatia to the European Union Member States

Vogler, Sabine; Habl, Claudia; Bogut, Martina; Vončina, Luka
April 2011
Croatian Medical Journal;Apr2011, Vol. 52 Issue 2, p183
Academic Journal
Aim: To perform a comparative analysis of the pharmaceutical pricing and reimbursement systems in Croatia and the 27 European Union (EU) Member States. Methods Knowledge about the pharmaceutical systems in Croatia and the 27 EU Member States was acquired by literature review and primary research with stakeholders. Results: Pharmaceutical prices are controlled at all levels in Croatia, which is also the case in 21 EU Member States. Like many EU countries, Croatia also applies external price referencing, ie, compares prices with other countries. While the wholesale remuneration by a statutorily regulated linear mark-up is applied in Croatia and in several EU countries, the pharmacy compensation for dispensing reimbursable medicines in the form of a flat rate service fee in Croatia is rare among EU countries, which usually apply a linear or regressive pharmacy mark-up scheme. Like in most EU countries, the Croatian Social Insurance reimburses specific medicines at 100%, whereas patients are charged copayments for other reimbursable medicines. Criteria for reimbursement include the medicine’s importance from the public health perspective, its therapeutic value, and relative effectiveness. In Croatia and in many EU Member States, reimbursement is based on a reference price system. Conclusion: The Croatian pharmaceutical system is similar to those in the EU Member States. Key policies, like external price referencing and reference price systems, which have increasingly been introduced in EU countries are also applied in Croatia and serve the same purpose: to ensure access to medicines while containing public pharmaceutical expenditure.


Related Articles

  • Australian PBS announces new listings and price changes.  // PharmacoEconomics & Outcomes News;10/15/2011, Issue 639, p9 

    The article reports that medicines on the pharmaceutical benefits scheme (PBS) will be subsidize by the Australian government. The subsidy will also cover drugs that were deferred in February 2011 for fiscal reasons, but will be included in the list due to Pharmaceutical Benefits Advisory...

  • Global price interdependencies have significant impact.  // PharmacoEconomics & Outcomes News;8/9/2008, Issue 559, p3 

    The article claims that a model assessing the impact of global price interdependencies can help countries understand the implication of their external reference pricing policies for pharmaceutical products on the global repeated pricing game. But it notes that the focus given on assessment may...

  • The market side of biosimilars. Kirkner, Richard Mark // Drug Topics;Aug2015, Vol. 159 Issue 8, p20s 

    The article looks at challenges to be faced by biosimilars to gain a bigger share in the American therapeutics market. Topics include pricing based on longer and more expensive biosimilars development as compared to generic drugs, the use of nonproprietary names and formulary decisions on...

  • Prescription Solutions by OptumRx Receives 4th Consecutive TIPPSSM Certification for Pharmacy Benefits Transparency Standards.  // Biomedical Market Newsletter;9/26/2011, Vol. 21, p1331 

    The article reports that pharmacy benefit management (PBM) organization Prescription Solutions by OptumRx has received its 4th Transparency in Pharmaceutical Purchasing Solutions (TIPPS) SM certification from the HR Policy Association. It mentions that Prescription Solutions is among 5 PBMs that...

  • Cost Effectiveness of Dabrafenib as a First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in Canada. Delea, Thomas; Amdahl, Jordan; Wang, Alice; Amonkar, Mayur; Thabane, Marroon // PharmacoEconomics;Apr2015, Vol. 33 Issue 4, p367 

    Objective: To evaluate the cost effectiveness of dabrafenib versus dacarbazine and vemurafenib as first-line treatments in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma from a Canadian healthcare system perspective. Methods: A partitioned-survival analysis model...

  • Report from: India. Wan, Jane // Pharmaceutical Technology;Aug2013, Vol. 37 Issue 8, p32 

    The article discusses India's new 2013 Drug Price Control Order (DPCO) which replaced the 1995 version. It informs that new drug-pricing policy will affect two thirds of the Indian pharmaceutical industry. It mentions that the company IMS Health Inc. estimated an erosion of 290 million dollars...

  • NPPA rejects Cadila Healthcare's review plea against price fixation of dexamethasone injection.  // FRPT- Chemical Snapshot;12/7/2014, p17 

    The article reports on the rejection by the Indian National Pharmaceutical Pricing Authority (NPPA) of Cadila Healthcare's review application against fixation/revision of ceiling prices of dexamethasone injection in 2014. Topics covered include the submission by Cadila of a review application to...

  • Medicine's Deferred Promises. Weschler, Jill // Pharmaceutical Executive;Feb2009, Vol. 29 Issue 2, p13 

    The article focuses on the issues with drug pricing in the U.S. as well as the efforts in increasing access to affordable care. The analysis has indicated that 36 million patients left a prescription unfilled in 2007 due to medicine pricing issues, showing an increase of almost 12 million more...

  • Report from India. Wan, Jane // BioPharm International;Aug2013, Vol. 26 Issue 8, p8 

    The article looks at the drug-pricing policy of India. Under the Drug Pricing Control Order (DPCO) 2013, prices of 348 drugs under the National List of Essential Medicines (NLEM) 2011 are regulated by the National Pharmaceutical Pricing Policy 2012. The effect of the drug-pricing policy to...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics